FEDERAL COMMISSION FOR THE PROTECTION FROM SANITARY RISKS COFEPRIS

Regulatory perspective on emergency vaccines against ZIKV
Overview

1. Institutional Context
2. Legal Framework
3. Situation in Mexico
4. Regulatory Approval Process
What is COFEPRIS?

- The Federal Commission for the Protection from Sanitary Risks (COFEPRIS) in coordination with the States (Federal Sanitary Sistem) is the agency that allows the Mexican State to enforce the constitutional provision of health protection through the following:

1. **Sanitary Regulation**
   - Set of legal dispositions to control processes, products, methods, establishments, services and activities.

2. **Sanitary Control**
   - Set of actions of outreach sampling, inspection and when applicable safety measures and sanctions.

3. **Sanitary Promotion**
   - Set of actions aimed to promote the continuous improvement of the sanitary conditions of the processes, products, methods, establishments and services.
To protect population from sanitary risks derived from the use and consumption of goods and services, as well as from exposure to environmental and occupational factors, through prevention, regulation and sanitary inspection against said risks.
FEDERAL COMMISSIONER

- General Coordination of the Federal Sanitary System
- General Coordination of Legal Affairs
- Evidence and Management of Sanitary Risks
- Sanitary Promotion
- Sanitary Authorization
- Sanitary Enforcement
- Analytical Control and Coverage Extension
LEGAL FRAMEWORK

**GENERAL HEALTH LAW**
- Sanitary registry for medicines (Art. 376)
- Good manufacturing practices (Art. 222)

**Regulation for Health Supplies**
- Requirements for the sanitary Registry (Art. 157, 165, 167, 168, 169)
- Requirements for the variations of the Sanitary Registry (Art. 185)
- Requirements for the renew of the Sanitary Registry (Art. 190 bis 1 y 2)

**AGREEMENT** for which are acknowledged the proceedings and services, as formats that apply the Ministry of Health, through the Federal Commission for Protection against Sanitary Risks, subscribed in the Federal Proceedings And Services Registry of the Regulatory Improvement Federal Commission DOF-28-01-2011.

Requirements for the sanitary registry of new medicines, by variations or renew in different modalities.
Situation in Mexico – States with confirm cases of ZIKV infection

314 cases of ZIKV infection were confirmed
## Situation in Mexico – States with confirm cases of ZIKV infection

### Confirm Cases of ZIKV infection – Mexico 2015-2016

<table>
<thead>
<tr>
<th>State</th>
<th>Number of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chiapas</td>
<td>133</td>
</tr>
<tr>
<td>Oaxaca</td>
<td>126</td>
</tr>
<tr>
<td>Guerrero</td>
<td>24</td>
</tr>
<tr>
<td>Veracruz</td>
<td>8</td>
</tr>
<tr>
<td>Tabasco</td>
<td>7</td>
</tr>
<tr>
<td>Nuevo León</td>
<td>5</td>
</tr>
<tr>
<td>Jalisco</td>
<td>4</td>
</tr>
<tr>
<td>Michoacán</td>
<td>4</td>
</tr>
<tr>
<td>Nayarit</td>
<td>1</td>
</tr>
<tr>
<td>Sinaloa</td>
<td>1</td>
</tr>
<tr>
<td>Yucatán</td>
<td>1</td>
</tr>
</tbody>
</table>

Epidemiologic week No. 20
May 27, 2016
Situation in Mexico – Pregnant women – Confirm cases of ZIKV infection

89 cases of ZIKV infection were confirmed
### Situation in Mexico - Pregnant women – Confirm cases of ZIKV infection

<table>
<thead>
<tr>
<th>State</th>
<th>Number of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chiapas</td>
<td>50</td>
</tr>
<tr>
<td>Oaxaca</td>
<td>34</td>
</tr>
<tr>
<td>Guerrero</td>
<td>1</td>
</tr>
<tr>
<td>Veracruz</td>
<td>3</td>
</tr>
<tr>
<td>Jalisco</td>
<td>1</td>
</tr>
</tbody>
</table>

Epidemiologic week No. 20  
May 27, 2016

Regulatory Approval Process

**Pre-Marketing**

- Submission Dossier
- Protocol approval
- Clinical Trials
- CMN approval
- Evaluation Process of Medicines
- Group of experts in COFEPRIS, they only evaluate vaccines

**Post-Marketing**

- Advertising
- Marketing
- Pharmacovigilance
- Sanitary Registry
- 180 – 240 days
Regulatory Approval Process

CLINICAL TRIALS
- SAFETY
- EFFICACY

MANUFACTURING
- QUALITY

PRE CLINICAL AND CLINICAL INFORMATION
(Takes place in Mexico or others countries)

Microbiological and physicochemical information
GMP’s

All the information is pre review for the New Molecules Committee

• Regulation
• Approval
• Surveillance
The NMC is an instance of consultation, in the Committee is evaluated the information about safety, efficacy and quality of the new medicines or new indications for the purpose of registration, or products which require to be evaluated by groups of specialists.

The permanent members of the NMC are: Sanitary Authorisation Commissioner, Director of Marketing Authorisation, National Center of Pharmacovigilance, the Analytical Control and Coverage Extension Commission, the Mexican Institute of Industrial Property, Health institutes, Mexican Institute of Social Security (IMSS), the National Academy of medicine, among others.

The NMC has 4 meetings per week, so it is possible to review 1 product each meeting.

The technical opinion of the NMC is described in an official document. This document is sent to the manufacturer.
Art. 181. In case of a severe outbreak, communicable diseases, emergency situation or catastrophe that affects the country, the Ministry of Health define immediately the measures to prevent and control the health damage.

Art. 182. In case of an emergency that causes a risk for the population, the Ministry of Health define immediately the measures for the health protection.

Art. 183. The President could proclaim a national emergency. The president must have to inform the population by the official dairy of Mexico.
Requirements for accelerate evaluation

National Emergency proclaimed by the President or a Request of accelerate evaluation by Ministry of Health, in the context of the public health emergency

Manufacturer has to present to the NMC the following information:
- Production and quality control information
- Evidence of GMP’s
- Stability data
- Summary information on preclinical and clinical data
- Risk management plan

The Committee give an opinion and advice to COFEPRIS on the acceptability of the product for emergency use in the context of the public health emergency

Guideline with the information of the minimum data requirements in case of public health emergency
Requirements for accelerate evaluation

Internal Operative Procedure for the priority attention for the registration of medicines for serious diseases.

<table>
<thead>
<tr>
<th>Type of product</th>
<th>Official evaluation</th>
<th>Accelerated evaluation</th>
<th>Public health Emergency</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Molecule</td>
<td>180 - 240 days</td>
<td>60 working days</td>
<td>5 working days</td>
</tr>
</tbody>
</table>
Follow up process – Before the dossier submission

Clinical trials approval
- Phase I
- Phase II
- Phase III

Studies conducted in Mexico
- Subcommittee of developing products:
  - The manufacturer could present the preliminary results of all the studies:
    - Preclinical and clinical data
    - Quality information
    - Production information

New Molecules Committee:
- Production and quality control information
- Evidence of GMP's
- Stability data
- Information on preclinical and clinical data
- Risk management plan
Conclusion

- The manufacturer has to contact COFEPRIS as soon as possible, to have a follow up process and accelerate evaluation.

- Manufacturing quality information is needed: starting materials, production process, testing methods, specification,.

- Preclinical information. Manufacturer has to justify the choice of animal model. The preclinical information has to be complete.

- Preliminary data of clinical trials can be accepted to be evaluate for the Subcommittee and the Committee.

- Guideline with the information of the minimum data requirements in case of public health emergency, is generated by COFEPRIS, and will be published at the end of the year.
Thank You

mlara@cofepris.gob.mx
MARIA DE LA LUZ LARA MÉNDEZ

We are COFEPRIS, we are NRA